1_Prana Biotechnology Investor Presentation_2018-0627 final
Prana Biotechnology is pleased to announce it has received ethics committee approval and has commenced recruitment for its Phase I Clinical trial evaluating the safety, tolerability and pharmacokinetics of the Company’s lead drug candidate, PBT434, in healthy volunteers.
Prana Biotechnology will be presenting at the China Healthcare Investment & Partnering Symposium on Saturday 17 March 2018 at 9.30am China Standard Time. Please access the webcast via the following link: http://wsw.com/webcast/brileyco20/pran/ The webcast will be archived for 90 days following the presentation.
Dr. David Stamler will be presenting at the China Healthcare Investment & Partnering Symposium on Saturday 17 March 2018 at 9.30am China Standard Time.
Prana’s PBT434 prevents neuronal loss in a new model of neurodegeneration
Prana Biotechnology JPM investor presentation_updated
Dr. David Stamler presenting at Biotech Showcase
Prana has today announced that is has received a A$3.02 million cash refund under the Australian Government’s R&D Tax Incentive Scheme.
AGM Presentation 2017
Receive news from Alterity Therapeutics
